Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза III Россия

Laquinimod

A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS

Номер протоколаMS-LAQ-301
ФазаФаза III
Участников по плану — во всех странах исследования1 106
Сроки13.11.2007 — 08.11.2010
Начало: 13 ноября 2007Окончание: 8 ноября 2010
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00509145/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 18–55 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 1106 чел. во всех странах исследования.
  • Плановая дата окончания (11.2010) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст18–55 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 12 · невключение: 38

Критерии включения

  • Subjects must have a confirmed and documented MS diagnosis as defined by the Revised McDonald criteria \[Ann Neurol 2005: 58:840-846\], with a relapsing-remitting disease course.
  • Subjects must be ambulatory with converted Kurtzke EDSS score of 0-5.5.
  • Subjects must be in a stable neurological condition and free of corticosteroid treatment \[intravenous (iv), intramuscular (im) and/or per os (po)\] 30 days prior to screening (month -1).
  • Subjects must have had experienced one of the following:
  • At least one documented relapse in the 12 months prior to screening
  • At least two documented relapses in the 24 months prior to screening
  • One documented relapse between 12 and 24 months prior to screening with at least one documented T1-Gd enhancing lesion in an MRI performed within 12 months prior to screening.
  • Subjects must be between 18 and 55 years of age, inclusive.
  • Subjects must have disease duration of at least 6 months (from the first symptom) prior to screening.
  • Women of child-bearing potential must practice an acceptable method of birth control \[acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptive, contraceptive patch, long-acting injectable contraceptive, partner's vasectomy or double-barrier method (condom or diaphragm with spermicide).
  • Subjects must be able to sign and date a written informed consent prior to entering the study
  • Subjects must be willing and able to comply with the protocol requirements for the duration of the study.

Критерии невключения

  • Subjects with progressive forms of MS
  • An onset of relapse, unstable neurological condition or any treatment with corticosteroids \[intravenous (iv), intramuscular (im) and/or per os (po)\] or ACTH between month -1 (screening) and 0 (baseline).
  • Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.
  • Use of immunosuppressive including Mitoxantrone (Novantrone®) or cytotoxic agents within 6 months prior to the screening visit.
  • Previous use of either of the following: natalizumab (Tysabri®), cladribine, laquinimod.
  • Previous treatment with glatiramer acetate (Copaxone®) Interferon-β (either 1a or 1b) or IVIG within 2 months prior to screening visit.
  • Systemic corticosteroid treatment of ≥30 consecutive days duration within 2 months prior to screening visit.
  • Previous total body irradiation or total lymphoid irradiation.
  • Previous stem cell treatment, autologous bone marrow transplantation or allogenic bone marrow transplantation.
  • A known history of tuberculosis.
  • Acute infection two weeks prior to baseline visit.
  • Major trauma or surgery two weeks prior to baseline
  • A history of vascular thrombosis (excluding catheter-site superficial venous thrombophlebitis).
  • A carrier state of factor V Leiden mutation (either homo- or heterozygous) as disclosed at screening.
  • Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or HIV antibody as disclosed at screening visit.
  • Use of potent inhibitors of CYP3A4 within 2 weeks prior to baseline visit (1 month for fluoxetine) see detailed list in Appendix 5
  • Use of amiodarone within 2 years prior to screening visit.
  • Pregnancy or breastfeeding.
  • Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation, as determined by medical history, physical examinations, ECG, laboratory tests or chest X-ray. Such conditions may include:
  • A cardiovascular or pulmonary disorder that cannot be well-controlled by standard treatment permitted by the study protocol.
  • A gastrointestinal disorder that may affect the absorption of study medication.
  • Renal or metabolic diseases.
  • Any form of chronic liver disease, including known non-alcoholic steatohepatitis.
  • A ≥2xULN serum elevation of either of the following at screening: ALT, AST or direct bilirubin
  • A QTC interval (obtained from either 2 ECG recordings at screening or from the mean value calculated from 3 measurements at baseline visit) which is >450msec.
  • A family history of Long- QT syndrome.
  • A history of drug and/or alcohol abuse.
  • Major psychiatric disorder.
  • A known history of sensitivity to Gd.
  • Inability to successfully undergo MRI scanning.
  • Known drug hypersensitivity that would preclude administration of laquinimod, such as hypersensitivity to: mannitol, meglumine or sodium stearyl fumarate.
  • Exclusion Criteria:
  • Subjects who suffer from any form of progressive MS.
  • Any condition which the investigator feels may interfere with participation in the study.
  • Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,
  • Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening
  • Previous treatment with immunomodulators within two months prior to screening
  • Pregnancy or breastfeeding.

Источник: ClinicalTrials.gov, NCT00509145 · запись обновлена в реестре 2 ноября 2021.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Включено участников (факт, все страны)1 106
Что измеряют — первичные конечные точки (1), вторичных — 4
  • Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period — Up to Month 24

Цель исследования

Determination the efficacy of daily oral treatment with laquinimod 0.6 mg capsules as compared to placebo in subjects with Relapsing Remitting Multiple Sclerosis (RRMS).

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00509145 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.